Sara A. Hurvitz, MD

Articles

Practical Advice on the Management of TNBC

August 2nd 2022

Before closing out their conversation on metastatic triple-negative breast cancer, expert oncologists share a few clinical pearls on optimizing TNBC management.

Addressing Unmet Needs in the Management of TNBC

August 2nd 2022

Perspectives on the most prominent unmet needs in metastatic triple-negative breast cancer and how these may be addressed with future clinical trials.

Novel ADCs Under Investigation in Triple-Negative Breast Cancer

July 25th 2022

Expert oncologists review novel ADCs in TNBC and consider how their approval may impact sequencing of therapy in this setting.

Metastatic TNBC: Safety, Efficacy, and Quality of Life With Sacituzumab Govitecan

July 25th 2022

Comprehensive discussion on the safety and efficacy profile of the antibody-drug conjugate (ADC) sacituzumab govitecan and managing ADC-related adverse events in patients with mTNBC.

Optimizing Treatment Strategies in Breast Cancer: Q&A

June 8th 2022

Fielding questions from their live audience, Joyce O'Shaughnessy, MD, and Sara Hurvitz, MD, discuss optimal selection of therapy for patients with breast cancer.

Clinical Trials in HER2+ mBC: DESTINY-Breast03 and HER2CLIMB

June 8th 2022

Highlights of the results from the DESTINY-Breast03 and HER2CLIMB trials, evaluating T-DXd and tucatinib, respectively, in HER2+ metastatic breast cancer.

Patient Scenario: HER2+ Metastatic Breast Cancer

June 1st 2022

Joyce O'Shaughnessy, MD, and Sara Hurvitz, MD, consider how they would approach the treatment of a patient with HER2+ metastatic breast cancer.

KEYNOTE-522: Neoadjuvant and Adjuvant Pembrolizumab in TNBC

June 1st 2022

Expert perspectives on adjuvant and neoadjuvant use of pembrolizumab in the KEYNOTE-522 study in triple-negative breast cancer.

Selecting Novel Adjuvant Therapy For Patients With Breast Cancer

May 25th 2022

Following their discussion on the OlympiA and monarchE trials in breast cancer, experts consider when they would use olaparib or abemaciclib in the adjuvant setting.

Adjuvant Abemaciclib in Early Breast Cancer: The monarchE Trial

May 25th 2022

Shared insight on the monarchE trial, which studied adjuvant abemaciclib in patients with HR+, HER2- high-risk early breast cancer.

Impact of Molecular Testing on Treatment Options in Breast Cancer

May 11th 2022

Shared insight on specific treatment options in breast cancer made available when patients are found to have actionable targets via molecular testing.

Molecular Testing Platforms in Breast Cancer

May 11th 2022

Expert perspectives on platforms for molecular testing in breast cancer, as well as the actionable targets that treating physicians should be looking for.

SABCS 2021 Updates in Key Clinical Trials for Breast Cancer

February 14th 2022

Patrick Neven MD, PhD; Sara A. Hurvitz, MD; Kevin Kalinsky, MD, MS; and Aditya Bardia, MD, MPH, share insight on updates in key clinical trials and novel therapies in breast cancer presented at SABCS 2021.

SABCS 2021 Updates in CDK4/6 Inhibitors in Breast Cancer

February 7th 2022

Sara A. Hurvitz, MD; Aditya Bardia, MD, MPH; Patrick Neven, MD, PhD; and Kevin Kalinsky MD, MS, discuss SABCS 2021 updates on the use of CDK4/6 inhibitors in HR+/HER2 breast cancer.

SABCS 2021 Updates in ER+ Breast Cancer

January 31st 2022

Experts in the management of breast cancer review recent data on SERDs (selective estrogen receptor degraders) in ER+/HER2 advanced breast cancer presented at SABCS [San Antonio Breast Cancer Symposium] 2021.

Dr. Hurvitz on the Key Objectives of DESTINY-Breast03 in HER2+ Breast Cancer

December 21st 2021

Sara A. Hurvitz, MD, discusses the rationale for the phase 3 DESTINY-Breast03 trial examining in HER2-positive breast cancer.

Advances Treating HR+ Metastatic Breast Cancer

December 6th 2021

Various breast oncologists discuss the potential effect of treatment advances in hormone receptor-positive metastatic breast cancer.

Novel Therapies Under Investigation for HR+ MBC

December 6th 2021

An overview of key presentations from ESMO 2021 that continues studying the potential effect of novel-based treatment options for use in hormone receptor-positive metastatic breast cancer.

PI3K Inhibitors for HR+ MBC

November 29th 2021

The relevance of PIK3CA mutations in terms of the pathophysiology of HR-positive metastatic breast cancer, and lessons learned in practice and via clinical studies in terms of sequencing therapy with PI3K inhibitors.

HR+ MBC: Palbociclib Plus Endocrine Therapy on Time to Chemotherapy

November 22nd 2021

The rationale for conducting a post-hoc analysis of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor-positive metastatic breast cancer as presented at ESMO 2021.